IPSC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jun 2024 @ 04:00):

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies...

Stats
今日成交量	86 539.00
平均成交量	123 677
市值	247.03M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $-0.500 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.340
ATR14	$0.0180 (0.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Russotti Gregory	Sell	5 000	Common Stock
2024-05-06	Russotti Gregory	Sell	5 000	Common Stock
2024-05-03	Carr Douglas	Sell	257	Common Stock
2024-05-03	Farid Adrienne	Sell	913	Common Stock
2024-04-22	Russotti Gregory	Sell	5 000	Common Stock

INSIDER POWER
70.67
Last 96 transactions
Buy: 10 700 785 \| Sell: 3 082 886

音量相关性

長: -0.12 (neutral)

短: 0.47 (neutral)

Signal:(46.052) Neutral

Century Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Century Therapeutics, 相关性 - 货币/商品

0.56
( weak )

-0.73
( moderate negative )

0.00
( neutral )

-0.07
( neutral )

-0.01
( neutral )

-0.06
( neutral )

Century Therapeutics, 财务报表

Annual	2023
营收:	$2.24M
毛利润:	$-10.81M (-483.62 %)
EPS:	$-2.30

FY	2023
营收:	$2.24M
毛利润:	$-10.81M (-483.62 %)
EPS:	$-2.30

FY	2022
营收:	$5.20M
毛利润:	$-4.87M (-93.71 %)
EPS:	$-2.27

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.759

Financial Reports:

No articles found.

Century Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Century Therapeutics,

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company\'s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.